Stay updated on Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.

Latest updates to the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page
- Check2 days agoChange DetectedUpdates the ClinicalTrials.gov page revision identifier from v3.5.2 to v3.5.3, reflecting a site/version change rather than a modification to the underlying trial record.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision history shows a new revision v3.5.0 added and an older revision v3.4.3 removed.SummaryDifference0.1%

- Check45 days agoChange DetectedThe revision history shows a new entry for v3.4.3 added and the previous v3.4.2 entry removed.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded Revision: v3.4.2 to the history; removed the funding notice and the earlier Revision: v3.4.1.SummaryDifference1.0%

- Check81 days agoChange DetectedAdded a Notice about a lapse in government funding stating that information may not be up to date and directing users to status sources. Updated the page revision to v3.4.1 and removed the previous v3.4.0 entry.SummaryDifference1.0%

Stay in the know with updates to Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.